These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 23836234)

  • 61. Faldaprevir for the treatment of genotype-1 hepatitis C virus.
    Agarwal K; Barnabas A
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):277-88. PubMed ID: 25633983
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New approaches in the treatment of hepatitis C.
    González-Grande R; Jiménez-Pérez M; González Arjona C; Mostazo Torres J
    World J Gastroenterol; 2016 Jan; 22(4):1421-32. PubMed ID: 26819511
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emerging therapies for the treatment of hepatitis C.
    Lange CM; Jacobson IM; Rice CM; Zeuzem S
    EMBO Mol Med; 2014 Jan; 6(1):4-15. PubMed ID: 24106239
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.
    Bhebhe L; Anderson M; Souda S; Choga WT; Zumbika E; Shaver ZM; Mbangiwa T; Phinius BB; Banda CC; Melamu P; Musonda RM; Essex M; Blackard JT; Moyo S; Gaseitsiwe S
    BMC Infect Dis; 2019 Oct; 19(1):875. PubMed ID: 31640596
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Antiviral agents for analyzing virus life cycle: chemical genetics for virology].
    Watashi K
    Yakugaku Zasshi; 2013; 133(11):1169-75. PubMed ID: 24189558
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Future hepatitis C virus treatment: interferon-sparing combinations.
    Gane E
    Liver Int; 2011 Jan; 31 Suppl 1():62-7. PubMed ID: 21205140
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New targets for treatment against HCV infection.
    Pan Q; van der Laan LJ
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):505-15. PubMed ID: 23199508
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Zhao Q; Xia N
    Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
    [No Abstract]   [Full Text] [Related]  

  • 75. Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response.
    Sallie R
    Virol J; 2007 Mar; 4():29. PubMed ID: 17355620
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.
    Imran M; Manzoor S; Khattak NM; Khalid M; Ahmed QL; Parvaiz F; Tariq M; Ashraf J; Ashraf W; Azam S; Ashraf M
    Arch Virol; 2014 May; 159(5):831-46. PubMed ID: 23979177
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.
    Ansaldi F; Orsi A; Sticchi L; Bruzzone B; Icardi G
    World J Gastroenterol; 2014 Aug; 20(29):9633-52. PubMed ID: 25110404
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.
    Lonardo A; Adinolfi LE; Restivo L; Ballestri S; Romagnoli D; Baldelli E; Nascimbeni F; Loria P
    World J Gastroenterol; 2014 Jun; 20(23):7089-103. PubMed ID: 24966582
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
    Molino S; Martin MT
    Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.